What is the price-to-earnings ratio of Evrofarma?
The price-earnings ratio of Evrofarma is currently 5.46.
Evrofarma P/E 2024
Evrofarma P/E
5.46
Ticker
EVROF.AT
ISIN
GRS385113006
As of Sep 20, 2024, Evrofarma's P/E ratio was 5.46, a -30.89% change from the 7.9 P/E ratio recorded in the previous year.
The Evrofarma P/E history
Evrofarma Aktienanalyse
What does Evrofarma do?
Evrofarma ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Evrofarma's P/E Ratio
The Price to Earnings (P/E) Ratio of Evrofarma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Evrofarma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Evrofarma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Evrofarma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Evrofarma stock
How has the price-earnings ratio of Evrofarma changed compared to last year?
The price-to-earnings ratio of Evrofarma has increased by -30.89% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Evrofarma high compared to other companies?
Yes, the price-to-earnings ratio of Evrofarma is high compared to other companies.
How does an increase in the price-earnings ratio of Evrofarma affect the company?
An increase in the price-earnings ratio of Evrofarma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Evrofarma affect the company?
A decrease in the price-earnings ratio of Evrofarma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Evrofarma?
Some factors that influence the price-earnings ratio of Evrofarma are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Evrofarma pay?
Over the past 12 months, Evrofarma paid a dividend of 0.01 EUR . This corresponds to a dividend yield of about 0.66 %. For the coming 12 months, Evrofarma is expected to pay a dividend of 0 EUR.
What is the dividend yield of Evrofarma?
The current dividend yield of Evrofarma is 0.66 %.
When does Evrofarma pay dividends?
Evrofarma pays a quarterly dividend. This is distributed in the months of July, August, August, October.
How secure is the dividend of Evrofarma?
Evrofarma paid dividends every year for the past 0 years.
What is the dividend of Evrofarma?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Evrofarma located?
Evrofarma is assigned to the 'Non-cyclical consumption' sector.
Wann musste ich die Aktien von Evrofarma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Evrofarma from 9/19/2024 amounting to 0.05 EUR, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did Evrofarma pay the last dividend?
The last dividend was paid out on 9/19/2024.
What was the dividend of Evrofarma in the year 2023?
In the year 2023, Evrofarma distributed 0 EUR as dividends.
In which currency does Evrofarma pay out the dividend?
The dividends of Evrofarma are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Evrofarma
Our stock analysis for Evrofarma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evrofarma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.